Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.60    -0.35 (-4.00%)
Bid:
8.20
Ask:
9.00
Spread: 0.80 (9.756%)
Market Cap: £55.03m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Progress with global OEM contract

22 Sep 2014 07:00

RNS Number : 1959S
Kromek Group PLC
22 September 2014
 



22 September 2014

 

Kromek Group plc

("Kromek" or the "Company")

 

Kromek Progresses to Second Year of Development Contract with Global OEM in CT Medical Imaging Markets

 

Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, is pleased to announce that a top four Original Equipment Manufacturer ("OEM") in the Computed Tomography ("CT") market has confirmed its decision to progress to the second year of a previously announced programme with the Company. Kromek has received a $1m exclusivity payment for the second year.

 

This payment is part of a programme that comes under Kromek's mutually exclusive development contract, worth up to $5.3m, with the OEM for developing and supplying Cadmium Zinc Telluride ("CZT") based multispectral (colour) detectors for producing high resolution colour X-Ray images by CT scanners. The decision to continue the programme for the second year was based on sustained progress towards meeting the aims of the development programme.

 

Arnab Basu, CEO of Kromek, said: "We are delighted to be progressing this project to advance colour CT imaging, which can lead to major healthcare benefits for diagnosis and treatment of cancers, cardiovascular diseases and other pathologies. With the success of our collaboration, our relationship with this key OEM partner continues to develop and grow stronger. This latest step is a clear endorsement of our technology and our long-term strategy to position Kromek's subcomponents at the heart of major global OEMs' medical imaging systems to improve diagnostic capabilities, resulting in better clinical outcomes."

 

This contract does not change the Company's expectations for the year ended 30 April 2015. However, it provides further evidence of the progress towards meeting market expectations.

 

Arnab Basu, CEO, and Derek Bulmer, CFO, will be hosting a webinar today at 12pm where they will give a presentation on their results for the year ended 30 April 2014. No additional disclosure will be made about financials or current trading further to the Company's announcement released on 28 August 2014. Analysts and investors wishing to join can register at:

https://attendee.gotowebinar.com/register/5530034774550287105

Enquiries

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

01740 626 060

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley - Corporate Finance

Charles Leigh-Pemberton - Broking

0207 886 2500

Luther Pendragon

Harry Chathli, Claire Norbury, Alexis Gore, Ivana Petkova

0207 618 9100

 

 

 

About Kromek Group plc

 

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 250 pieces of IP.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

 

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over a hundred full time employees across its global operations.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTEAENFADDLEAF
Date   Source Headline
4th Jun 20267:00 amRNSGrant of Long-Term Incentives
2nd Jun 20267:00 amRNS-RLaunch of new interactive investor hub
1st Jun 20267:00 amRNSPDMR/Director Shareholding, Issue of Equity & TVR
12th May 20267:00 amRNSFull Year 2026 Trading Update
30th Apr 20262:30 pmRNSIssue of Equity, TVR & Extension of Options
9th Mar 20261:36 pmRNSDirector Share Purchase
9th Mar 20261:36 pmRNSDirector Share Purchase
20th Jan 20267:00 amRNSInterim Results
16th Dec 20257:00 amRNSNotice of Results
15th Dec 202512:27 pmRNSHolding(s) in Company
3rd Nov 202511:32 amRNSDirector Share Purchase
28th Oct 20257:00 amRNSGrant of Options, PDMR Dealings and TVR
27th Oct 20252:16 pmRNSResult of AGM
27th Oct 20257:00 amRNSPre-close Trading Statement
3rd Oct 202510:06 amRNSNotice of AGM and Publication of Annual Report
16th Sep 20257:00 amRNSFinal Results
11th Aug 20257:00 amRNSNew Biosecurity Award from UK MoD
28th Jul 20257:00 amRNS$5m received under Siemens Healthineers agreement
21st Jul 20257:00 amRNS£1.7m contract win under UK Government Framework
23rd Jun 202511:40 amRNS-RCapital Markets Day Presentation
18th Jun 20257:00 amRNSCapital Markets Day
16th Jun 20254:02 pmRNSHolding(s) in Company
9th Jun 20257:00 amRNSIssue of Equity and Total Voting Rights
3rd Jun 20251:53 pmRNSHolding(s) in Company
3rd Jun 20257:00 amRNSCapital Markets Day
28th May 20257:00 amRNSNew Nuclear Security Orders
8th May 20257:05 amRNSDirectorate Change
8th May 20257:00 amRNSFull Year 2025 Trading Update
17th Feb 20257:00 amRNS$25m received under Siemens Healthineers agreement
7th Feb 20251:49 pmRNSHolding(s) in Company
6th Feb 202512:35 pmRNSHolding(s) in Company
30th Jan 20257:01 amRNSInterim Results
30th Jan 20257:00 amRNSKromek Signs Agreements with Siemens Healthineers
13th Dec 202412:20 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM and Publication of Annual Report
28th Oct 20247:01 amRNSFinal Results and Publication of Annual Report
28th Oct 20247:00 amRNSFinancing Update
30th Sep 20247:00 amRNSUpdate on Full Year Results
23rd Sep 20247:00 amRNSKromek selected for UK Government Framework
16th Sep 20247:00 amRNSKromek awarded £2.0m contract from UK MOD
21st Aug 202410:14 amRNSHolding(s) in Company
7th Jun 20249:20 amRNSCancellation of outstanding Convertible Loan Notes
29th May 20247:00 amRNSFY 2024 Trading Update
25th Apr 20247:00 amRNSKromek receives new Nuclear Security contract
3rd Apr 20243:13 pmRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSKromek receives $2.1m security screening order
6th Mar 20243:21 pmRNSHolding(s) in Company
4th Mar 202412:16 pmRNSHolding(s) in Company
4th Mar 202411:51 amRNSResult of General Meeting
5th Feb 202410:17 amRNSConversion of £1.5m of Convertible Loan Notes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.